Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Amy Yamamoto"'
Publikováno v:
Pain Management. 12:45-57
Aim: HTX-011 (ZYNRELEF™) is an extended-release, dual-acting local anesthetic containing bupivacaine and meloxicam. In bunionectomy and herniorrhaphy studies, HTX-011 resulted in less postoperative pain and less opioid consumption versus bupivacain
Autor:
Caroline A. Lee, Jesse Hall, Thomas Marbury, Jolene Kay Berg, Michael Gillen, Dongmei Zhou, David M. Wilson, William B. Smith, Michal Kazimir, Susan P. Walker, Amy Yamamoto, Zancong Shen
Publikováno v:
Clinical Drug Investigation
Background and Objective Verinurad (RDEA3170) is a high-affinity, selective URAT1 transporter inhibitor in development for treating gout and asymptomatic hyperuricemia. This Phase I, single-dose study investigated the pharmacokinetics, pharmacodynami
Autor:
Zancong Shen, Michael Gillen, Amy Yamamoto, Jesse Hall, Xiaohong Yan, Masanari Shiramoto, Yasushi Ito, Sha Liu
Publikováno v:
Rheumatology (Oxford, England)
Objectives Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter in clinical development for treating gout and asymptomatic hyperuricaemia. The aim of this Phase 2a, randomized, open-label study was to investigate the multiple-do
Autor:
George W. Ordal, Mikhail Piatibratov, Tracey Allen K. Freitas, Shaobin Hou, Ella A. Meleshkevitch, Randy W. Larsen, Victor Sivozhelezov, Amy Yamamoto, Mike Zimmer, Maqsudul Alam
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 98(16)
The recently discovered prokaryotic signal transducer HemAT, which has been described in both Archaea and Bacteria , mediates aerotactic responses. The N-terminal regions of HemAT from the archaeon Halobacterium salinarum (HemAT- Hs ) and from the Gr